Palatin Technologies Inc
PTN
Company Profile
Business description
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
Contact
103 Carnegie Center Drive
Suite 300
PrincetonNJ08852
USAT: +1 609 495-2200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
29
Stocks News & Analysis
stocks
ASX major bank drives strong quarterly profit
Profit momentum remains robust yet shares overvalued.
stocks
Ask the analyst: What to expect in earnings season?
The key metrics that matter this earnings season.
stocks
ASX healthcare share remains undervalued ahead of earnings
Margin recovery remains the key driver for this ASX healthcare share.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,040.50 | 12.90 | 0.14% |
| CAC 40 | 8,372.28 | 0.00 | 0.00% |
| DAX 40 | 25,099.00 | 335.88 | 1.36% |
| Dow JONES (US) | 51,947.25 | 235.60 | 0.46% |
| FTSE 100 | 10,736.23 | 97.06 | 0.91% |
| HKSE | 25,143.55 | 180.32 | 0.72% |
| NASDAQ | 24,975.82 | 161.87 | -0.64% |
| Nikkei 225 | 64,764.01 | 152.86 | 0.24% |
| NZX 50 Index | 13,807.31 | 35.02 | 0.25% |
| S&P 500 | 7,411.98 | 3.68 | 0.05% |
| S&P/ASX 200 | 8,870.50 | 12.60 | 0.14% |
| SSE Composite Index | 3,826.70 | 12.50 | 0.33% |